N-803 + carboplatin + nab-paclitaxel + ipilimumab + nivolumab

This is a combination regimen consisting of five agents used primarily in oncology clinical trials, especially for advanced or metastatic cancers such as non-small cell lung cancer. The components are: **N-803** (nogapendekin alfa inbakicept, formerly ALT‑803, brand name Anktiva): a novel interleukin‑15 receptor agonist and IL‑15 superagonist cytokine fusion protein that stimulates the proliferation and activation of natural killer cells and CD8+ T cells to enhance anti-tumor immunity[1][2][4][5][6][8]. Developed by ImmunityBio. **Carboplatin:** a platinum-based chemotherapy agent that induces DNA crosslinking and apoptosis in rapidly dividing tumor cells. Generic drug. **Nab-paclitaxel** (nanoparticle albumin-bound paclitaxel, brand name Abraxane): a microtubule inhibitor formulated with albumin nanoparticles to improve delivery; disrupts mitosis by stabilizing microtubules. Developed by Abraxis BioScience/Celgene/Bristol Myers Squibb. **Ipilimumab** (brand name Yervoy): a monoclonal antibody immune checkpoint inhibitor targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA‑4), enhancing T-cell mediated anti-tumor responses. Developed by Bristol Myers Squibb. **Nivolumab** (brand name Opdivo): an immune checkpoint inhibitor monoclonal antibody targeting programmed death 1 receptor (PD‑1), blocking its interaction with PD-L1/PD-L2 to restore T-cell function against tumors. Developed by Bristol Myers Squibb. This combination leverages both direct cytotoxic effects from chemotherapy and multiple immunotherapeutic mechanisms—cytokine stimulation via IL‑15 agonism, CTLA‑4 blockade, and PD‑1 inhibition—to maximize anti-tumor activity[6][7].

Brand names

Anktiva (for N-803)Abraxane (for nab-paclitaxel)Opdivo (for nivolumab)Yervoy (for ipilimumab)

Other names

NAI + nivolumab + ipilimumab + carboplatin + nab-paclitaxel